Depression and epilepsy: A bidirectional relation?

Epilepsia

Volumn 52, Issue SUPPL. 1, 2011, Pages 21-27

  Kanner, Andres M ^a  

^a RUSH MEDICAL COLLEGE   (United States)

Author keywords

Attention deficit hyperactivity disorder; Depression; Glutamate; Norepinephrine; Serotonin; Temporal lobe epilepsy

Indexed keywords

2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; 2 AMINO 3 (3,4 DICHLOROBENZYLOXY) 6 FLUOROBICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLIC ACID; 2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR; ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CITALOPRAM; DESIPRAMINE; DIZOCILPINE; EXCITATORY AMINO ACID TRANSPORTER; FLUOXETINE; GLUTAMATE DECARBOXYLASE; GLUTAMATE RECEPTOR 5; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMATE TRANSPORTER; GLUTAMIC ACID; KETAMINE; LITHIUM; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; PILOCARPINE; REBOXETINE; RILUZOLE; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; UNINDEXED DRUG;

ADD ON THERAPY; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL MODEL; ARTICLE; ATTENTION DEFICIT DISORDER; BIPOLAR DEPRESSION; BIPOLAR DISORDER; CARBON NUCLEAR MAGNETIC RESONANCE; COMORBIDITY; DEPRESSION; DISEASE ASSOCIATION; DISEASE MODEL; DISEASE PREDISPOSITION; EPILEPSY; EPILEPTOGENESIS; GENERALIZED EPILEPSY; GENETICALLY EPILEPSY PRONE RAT; HIPPOCAMPUS; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LIFE STRESS; MAJOR DEPRESSION; MATERNAL DEPRIVATION; MENTAL DISEASE; MOUSE; NERVE CELL NECROSIS; NEUROIMAGING; NEUROPATHOLOGY; NEUROTRANSMISSION; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; REPEATED DRUG DOSE; SEIZURE; SEPARATION ANXIETY; SEROTONIN RELEASE; SINGLE DRUG DOSE; TEMPORAL LOBE EPILEPSY; TUBEROUS SCLEROSIS;

ANIMALS; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; EPILEPSY; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MENTAL DISORDERS; PITUITARY-ADRENAL SYSTEM;

EID: 78651268507     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/j.1528-1167.2010.02907.x     Document Type: Article

References (69)

1. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH,. (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47: 351-354.
2. Bonanno G, Giambelli R, Raiteri L, Tiraboschi E, Zappettini S, Musazzi L, Raiteri M, Racagni G, Popoli M,. (2005) Chronic antidepressants reduce depolarization-evoked glutamate release and protein interactions favoring formation of SNARE complex in hippocampus. J Neurosci 25: 3270-3279.
3. Bowley MP, Drevets WC, Ongur D, Price JL,. (2002) Low glial numbers in the amygdala in major depressive disorder. Biol Psychiatry 52: 404-412.
4. Brambilla P, Perez J, Barale F, Schettini G, Soares JC,. (2003) GABAergic dysfunction in mood disorders. Mol Psychiatry 8: 721-737.
5. Bremner JD, Narayan M, Anderson ER, Staib LH, Miller HL, Charney DS,. (2000) Hippocampal volume reduction in major depression. Am J Psychiatry 157: 115-118.
6. Bremner JD, Vythilingam M, Vermetten E, Nazeer A, Adil J, Khan S, Staib LH, Charney DS,. (2002) Reduced volume of orbitofrontal cortex in major depression. Biol Psychiatry 51: 273-279.
7. Capizzano AA, Jorge RE, Acion LC, Robinson RG,. (2007) In vivo proton magnetic resonance spectroscopy in patients with mood disorders: a technically oriented review. J Magn Reson Imaging 26: 1378-1389.
8. Choudary PV, Molnar M, Evans SJ, Tomita H, Li JZ, Vawter MP, Myers RM, Bunney WE Jr, Akil H, Watson SJ, Jones EG,. (2005) Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci U S A 102: 15653-15658.
9. Clinckers R, Smolders I, Meurs A, Ebinger G, Michotte Y,. (2004) Anticonvulsant action of hippocampal dopamine and serotonin is independently mediated by D2 and 5-HT1A receptors. J Neurochem 89: 834-843.
10. Coffey CE,. (1994) The role of structural brain imaging in ECT. Psychopharmacol Bull 30: 477-483.
11. Cotter DR, Pariante CM, Everall IP,. (2001a) Glial cell abnormalities in major psychiatric disorders: the evidence and implications. Brain Res Bull 55: 585-595.
12. Cotter D, Mackay D, Landau S, Kerwin R, Everall I,. (2001b) Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. Arch Gen Psychiatry 58: 545-553.
13. Cotter D, Mackay D, Chana G, Beasley C, Landau S, Everall IP,. (2002) Reduced neuronal size and glial cell density in area 9 of the dorsolateral prefrontal cortex in subjects with major depressive disorder. Cereb Cortex 12: 386-394.
14. Crossin KL, Tai MH, Krushel LA, Mauro VP, Edelman GM,. (1997) Glucocorticoid receptor pathways are involved in the inhibition of astrocyte proliferation. Proc Natl Acad Sci U S A 94: 2687-2692.
15. Dager SR, Friedman SD, Parow A, Demopulos C, Stoll AL, Lyoo IK, Dunner DL, Renshaw PF,. (2004) Brain metabolic alterations in medication-free patients with bipolar disorder. Arch Gen Psychiatry 61: 450-458.
16. Favale E, Rubino V, Mainardi P, Lunardi G, Lunardi G, Albano C,. (1995) The anticonvulsant effect of fluoxetine in humans. Neurology 45: 1926-1927.
17. Favale E, Audenino D, Cocito L, Albano C,. (2003) The anticonvulsant effect of citalopram as an indirect evidence of serotonergic impairment in human epileptogenesis. Seizure 12: 316-318.
18. Forsgren L, Nystrom L,. (1999) An incident case referent study of epileptic seizures in adults. Epilepsy Res 6: 66-81.
19. Gilby KL, Sydserff S, Patey AM, Thorne V, St-Onge V, Jans J, McIntyre DC,. (2009) Postnatal epigenetic influences on seizure susceptibility in seizure-prone versus seizure-resistant rat strains. Behav Neurosci 123: 337-346.
20. Hasler G, Bonwetsch R, Giovacchini G, Toczek MT, Bagic A, Luckenbaugh DA, Drevets WC, Theodore WH,. (2007) 5-HT(1A) receptor binding in temporal lobe epilepsy patients with and without major depression. Biol Psychiatry 62: 1258-1264.
21. Heckers S, Stone D, Walsh J, Shick J, Koul P, Benes FM,. (2002) Differential hippocampal expression of glutamic acid decarboxylase 65 and 67 messenger RNA in bipolar disorder and schizophrenia. Arch Gen Psychiatry 59: 521-529.
22. Hesdorffer DC, Hauser WA, Annegers JF, Cascino G,. (2000) Major depression is a risk factor for seizures in older adults. Ann Neurol 47: 246-249.
23. Hesdorffer DC, Hauser WA, Olafsson E, Ludvigsson P, Kjartansson O,. (2006) Depression and suicidal attempt as risk factor for incidental unprovoked seizures. Ann Neurol 59: 35-41.
24. Hitiris N, Mohanraj R, Norrie J, Sills GJ, Brodie MJ,. (2007) Predictors of pharmacoresistant epilepsy. Epilepsy Res 75: 192-196.
25. Jobe PC,. (2006) Affective disorder and epilepsy comorbidity in the genetically epilepsy prone-rat (GEPR). In, Gilliam F, Kanner AM, Sheline YI, (Eds) Depression and brain dysfunction. Taylor & Francis, London, pp. 121-157.
26. Jobe PC, Mishra PK, Browning RA, Wang C, Adams-Curtis LE, Ko KH, Dailey JW,. (1994) Noradrenergic abnormalities in the genetically epilepsy-prone rat. Brain Res Bull 35: 493-504.
27. Jones NC, Salzberg MR, Kumar G, Couper A, Morris MJ, O'Brien TJ,. (2008) Elevated anxiety and depressive-like behavior in a rat model of genetic generalized epilepsy suggesting common causation. Exp Neurol 209: 254-260.
28. Jones NC, Kumar G, O'Brien TJ, Morris MJ, Rees SM, Salzberg MR,. (2009) Anxiolytic effects of rapid amygdala kindling, and the influence of early life experience in rats. Behav Brain Res 203: 81-87.
29. Kanner AM,. (2009) Depression and epilepsy: a review of multiple facets of their close relation. Neurol Clin 27: 865-880.
30. Kanner AM, Byrne R, Chicharro A, et al. (2009) A lifetime psychiatric history predicts a worse seizure outcome following temporal lobectomy. Neurology 72: 793-799.
31. Katoh-Semba R, Asano T, Ueda H, Morishita R, Takeuchi IK, Inaguma Y, Kato K,. (2002) Riluzole enhances expression of brain-derived neurotrophic factor with consequent proliferation of granule precursor cells in the rat hippocampus. FASEB J 16: 1328-1330.
32. Kugaya A, Sanacora G,. (2005) Beyond monoamines: glutamatergic function in mood disorders. CNS Spectr. 10: 808-819.
33. Kumar G, Couper A, O'Brien TJ, Salzberg MR, Jones NC, Rees SM, Morris MJ,. (2007) The acceleration of amygdala kindling epileptogenesis by chronic low-dose corticosterone involves both mineralocorticoid and glucocorticoid receptors. Psychoneuroendocrinology. 32: 834-842.
34. López JF, Chalmers DT, Little KY, Watson SJ,. (1998) Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression. Biol Psychiatry 43: 547-573.
35. Machado-Vieira R, Salvadore G, Ibrahim LA, Diaz-Granados N, Zarate CA Jr,. (2009) Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders. Curr Pharm Des 15: 1595-1611.
36. Mason GF, Sanacora G, Hundal R, et al. (2001) Preliminary evidence of reduced cortical GABA synthesis rate in major depression. Soc Neurosci. Abstr 142.6.
37. Mazarati AM, Siddarth P, Baldwin RA, Shin D, Caplan R, Sankar R,. (2008) Depression after status epilepticus: behavioural and biochemical deficits and effects of fluoxetine. Brain 131: 2071-2083.
38. Mazarati AM, Shin D, Kwon YS, Bragin A, Pineda E, Tio D, Taylor AN, Sankar R,. (2009) Elevated plasma corticosterone level and depressive behavior in experimental temporal lobe epilepsy. Neurobiol Dis 34: 457-461.
39. McCullumsmith RE, Meador-Woodruff JH,. (2002) Striatal excitatory amino acid transporter transcript expression in schizophrenia, bipolar disorder, and major depressive disorder. Neuropsychopharmacology. 26: 368-375.
40. Meldrum BS, Anlezark GM, Adam HK, Greenwood DT,. (1982) Anticonvulsant and proconvulsant properties of viloxazine hydrochloride: pharmacological and pharmacokinetic studies in rodents and the epileptic baboon. Psychopharmacology (Berl) 76: 212-217.
41. Öngür D, Drevets WC, Price JL,. (1998) Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci U S A 95: 13290-13295.
42. Piette Y, Delaunois AL, De Shaepdryver AF, Heymans C,. (1963) Imipramine and electroshock threshold. Arch Int Pharmacodyn Ther 144: 293-297.
43. Polc P, Schneeberger J, Haefely W,. (1979) Effects of several centrally active drugs on the sleep wakefulness cycle of cats. Neuropharmacology 18: 259-267.
44. Rajkowska G, Miguel-Hidalgo JJ, Wei J, Dilley G, Pittman SD, Meltzer HY, Overholser JC, Roth BL, Stockmeier CA,. (1999) Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 45: 1085-1098.
45. Rajkowska G, Halaris A, Selemon LD,. (2001) Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biol Psychiatry 49: 741-752.
46. Robinson R, Drafts B, Fisher J,. (2003) Fluoxetine increases GABAA receptor activity through a novel modulatory site. J Pharmcol Experimental Ther, 304: 978-984.
47. Rosenberg DR, Mirza Y, Russell A, Tang J, Smith JM, Banerjee SP, Bhandari R, Rose M, Ivey J, Boyd C, Moore GJ,. (2004) Reduced anterior cingulate glutamatergic concentrations in childhood OCD and major depression versus healthy controls. J Am Acad of Child Adolesc Psychiatry. 43: 1146-1153.
48. Salzberg M, Kumar G, Supit L, Jones NC, Morris MJ, Rees S, O'Brien TJ,. (2007) Early postnatal stress confers enduring vulnerability to limbic epileptogenesis. Epilepsia 48: 2079-2085.
49. Sanacora G, Mason GF, Rothman DL, Krystal JH,. (2002) Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am J Psychiatry 159: 663-665.
50. Sanacora G, Kendell SF, Levin Y, Simen AA, Fenton LR, Coric V, Krystal JH,. (2007) Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry 61: 822-825.
51. Sapolsky RM,. (2000a) The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death. Biol Psychiatry 48: 755-765.
52. Sapolsky RM,. (2000b) Glucocorticoids and Hippocampal Atrophy in Neuropsychiatric Disorders. Arch Gen Psychiatry 57: 925-935.
53. Sargent PA, Kjaer KH, Bench CJ, Rabiner EA, Messa C, Meyer J, Gunn RN, Grasby PM, Cowen PJ,. (2000) Brain serotonin 1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry 57: 174-180.
54. Sheline YI,. (2006) Brain structural changes associated with depression. In, Gilliam F, Kanner AM, Sheline YI, (Eds) Depression and brain dysfunction. Taylor & Francis, London, pp. 85-104.
55. Shirayama Y, Chen AC, Nakagawa S, Russell DS, Duman RS,. (2002) Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 22: 3251-3261.
56. Specchio LM, Iudice A, Specchio N, La Neve A, Spinelli A, Galli R, Rocchi R, Ulivelli M, de Tommaso M, Pizzanelli C, Murri L,. (2004) Citalopram as treatment of depression in patients with epilepsy. Clin Neuropharmacol 27: 133-136.
57. Theodore WH, Giovacchini G, Bonwetsch R, Bagic A, Reeves-Tyer P, Herscovitch P, Carson RE,. (2006) The effect of antiepileptic drugs on 5-HT-receptor binding measured by positron emission tomography. Epilepsia 47: 499-503.
58. Toczek MT, Carson RE, Lang L, Ma Y, Spanaki MV, Der MG, Fazilat S, Kopylev L, Herscovitch P, Eckelman WC, Theodore WH,. (2003) PET imaging of 5-HT1A receptor binding in patients with temporal lobe epilepsy. Neurology 60: 749-756.
59. Walter M, Henning A, Grimm S, Schulte RF, Beck J, Dydak U, Schnepf B, Boeker H, Boesiger P, Northoff G,. (2009) The relationship between aberrant neuronal activation in the pregenual anterior cingulate, altered glutamatergic metabolism, and aanhedonia in major depression. Arch Gen Psychiatry 66: 478-486.
60. Yanagita T, Wakasa Y, Kiyohara H,. (1980) Drug-dependance potential of viloxazine hydrochloride tested in rhesus monkeys. Pharmacol Biochem Behav 12: 155-161.
61. Ye Z, Lu Y, Sun H, Cheng H, Xu T, Zhou J,. (2008) Fluoxetine inhibition of glycine receptor activity in rat hippocampal neurons. Brain Research, 1239: 77-84.
62. Yildiz-Yesiloglu A, Ankerst DP,. (2006) Review of 1H magnetic resonance spectroscopy findings in major depressive disorder: a meta-analysis. Psychiatry Res 147: 1-25.
63. Zarate CA, Quiroz J, Payne J, Manji HK,. (2002) Modulators of the glutamatergic system: implications for the development of improved therapeutics in mood disorders. Psychopharmacol Bull 36: 35-83.
64. Zarate CA Jr, Payne JL, Quiroz J, Sporn J, Denicoff KK, Luckenbaugh D, Charney DS, Manji HK,. (2004) An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry 161: 171-174.
65. Zarate CA Jr, Quiroz JA, Singh JB, Denicoff KD, De Jesus G, Luckenbaugh DA, Charney DS, Manji HK,. (2005) An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry 57: 430-432.
66. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK,. (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63: 856-864.
67. Zeng LH, Bero AW, Zhang B, Holtzman DM, Wong M,. (2010) Modulation of astrocyte glutamate transporters decreases seizures in a mouse model of Tuberous Sclerosis Complex. Neurobiol Dis 37: 764-771.
68. Zink M, Vollmayr B, Gebicke-Haerter PJ, Henn FA,. (2010) Reduced expression of glutamate transporters vGluT1, EAAT2 and EAAT4 in learned helpless rats, an animal model of depression. Neuropharmacology 58: 465-473.
69. Zobel A, Wellmer J, Schulze-Rauschenbach S, Pfeiffer U, Schnell S, Elger C, Maier W,. (2004) Impairment of inhibitory control of the hypothalamic pituitary adrenocortical system in epilepsy. Eur Arch Psychiatry Clin Neurosci 254: 303-311.